TF Stoop
@tfstoop.bsky.social
MD, PhD candidate HPB Surgery Amsterdam UMC 🇳🇱| Former Research Fellow Karolinska University Hospital 🇸🇪 & University of Colorado 🇺🇸
Pinned
TF Stoop
@tfstoop.bsky.social
· Apr 5
Published in @thelancet.bsky.social, our review on #PancreaticCancer
📎Epidemiology🌎
📎Pathogenesis🔬
📎Risk factors & surveillance🕵️
📎Diagnostics🩺
📎Treatment💊
📎Future directions🔍
… by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.
📎Epidemiology🌎
📎Pathogenesis🔬
📎Risk factors & surveillance🕵️
📎Diagnostics🩺
📎Treatment💊
📎Future directions🔍
… by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.
Reposted by TF Stoop
It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @thelancet.com
Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR
⚖️ No difference in overall survival
😰 Serious adverse events 40%
👍 Both regimens may be considered
www.thelancet.com/pdfs/journal...
Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR
⚖️ No difference in overall survival
😰 Serious adverse events 40%
👍 Both regimens may be considered
www.thelancet.com/pdfs/journal...
September 11, 2025 at 8:29 AM
It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @thelancet.com
Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR
⚖️ No difference in overall survival
😰 Serious adverse events 40%
👍 Both regimens may be considered
www.thelancet.com/pdfs/journal...
Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR
⚖️ No difference in overall survival
😰 Serious adverse events 40%
👍 Both regimens may be considered
www.thelancet.com/pdfs/journal...
Reposted by TF Stoop
This population-based study on the NCCN resectability stages of pancreatic adenocarcinoma indicates that the rate of LAPC was lower than reported in literature, whereas the rate of PRPC is higher
Resectability stages of pancreatic cancer: nationwide reference
At diagnosis, pancreatic adenocarcinoma is categorized into resectability stages based on extent of vascular involvement and presence of metastases at cros
doi.org
August 7, 2025 at 3:22 PM
This population-based study on the NCCN resectability stages of pancreatic adenocarcinoma indicates that the rate of LAPC was lower than reported in literature, whereas the rate of PRPC is higher
Published in @bjsurgery.bsky.social, unique nationwide 🇳🇱 data @dpcgofficial.bsky.social on #NCCN resectability staging of #PancreaticCancer at diagnosis:
🧷 23% PRPC
🧷 8% BRPC
🧷 11% LAPC
🧷 58% M1
… including stratification for tumour location.
👉 academic.oup.com/bjs/article/...
🧷 23% PRPC
🧷 8% BRPC
🧷 11% LAPC
🧷 58% M1
… including stratification for tumour location.
👉 academic.oup.com/bjs/article/...
August 7, 2025 at 6:02 AM
Published in @bjsurgery.bsky.social, unique nationwide 🇳🇱 data @dpcgofficial.bsky.social on #NCCN resectability staging of #PancreaticCancer at diagnosis:
🧷 23% PRPC
🧷 8% BRPC
🧷 11% LAPC
🧷 58% M1
… including stratification for tumour location.
👉 academic.oup.com/bjs/article/...
🧷 23% PRPC
🧷 8% BRPC
🧷 11% LAPC
🧷 58% M1
… including stratification for tumour location.
👉 academic.oup.com/bjs/article/...
Reposted by TF Stoop
HPB Journal Highlight ⭐️Ishida et al. Global survey shows big variation in how surgeons manage neck of pancreas cancers, especially with vascular involvement. Highlights the need for future studies & clearer guidelines! 🔗https://tinyurl.com/3myun89t 📊🌎 #PancreaticCancer #HPBSurgery
July 29, 2025 at 9:41 AM
HPB Journal Highlight ⭐️Ishida et al. Global survey shows big variation in how surgeons manage neck of pancreas cancers, especially with vascular involvement. Highlights the need for future studies & clearer guidelines! 🔗https://tinyurl.com/3myun89t 📊🌎 #PancreaticCancer #HPBSurgery
Reposted by TF Stoop
Distribution of the NCCN stages of #PancreaticCancer ?
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
July 11, 2025 at 8:59 PM
Distribution of the NCCN stages of #PancreaticCancer ?
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
Published in #BJC, our 🌎 study with 935 localized #pancreaticancer patients after resection, comparing preoperative FFX vs GnP:
📎FFX vs GnP not associated with OS (p=0.17)
📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology
🚨Pragmatic RCT #chemosensitivitymarkers🔍
👉 www.nature.com/articles/s41...
📎FFX vs GnP not associated with OS (p=0.17)
📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology
🚨Pragmatic RCT #chemosensitivitymarkers🔍
👉 www.nature.com/articles/s41...
May 7, 2025 at 8:03 AM
Published in #BJC, our 🌎 study with 935 localized #pancreaticancer patients after resection, comparing preoperative FFX vs GnP:
📎FFX vs GnP not associated with OS (p=0.17)
📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology
🚨Pragmatic RCT #chemosensitivitymarkers🔍
👉 www.nature.com/articles/s41...
📎FFX vs GnP not associated with OS (p=0.17)
📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology
🚨Pragmatic RCT #chemosensitivitymarkers🔍
👉 www.nature.com/articles/s41...
Reposted by TF Stoop
Immensely honored to receive a Honorary Fellowship with #ASA #American #Surgical #Association #AnnalsOfSurgery in #SanDiego
April 24, 2025 at 8:44 PM
Immensely honored to receive a Honorary Fellowship with #ASA #American #Surgical #Association #AnnalsOfSurgery in #SanDiego
Reposted by TF Stoop
Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
April 24, 2025 at 3:01 PM
Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
Published in @thelancet.bsky.social, our review on #PancreaticCancer
📎Epidemiology🌎
📎Pathogenesis🔬
📎Risk factors & surveillance🕵️
📎Diagnostics🩺
📎Treatment💊
📎Future directions🔍
… by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.
📎Epidemiology🌎
📎Pathogenesis🔬
📎Risk factors & surveillance🕵️
📎Diagnostics🩺
📎Treatment💊
📎Future directions🔍
… by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.
April 5, 2025 at 7:02 AM
Published in @thelancet.bsky.social, our review on #PancreaticCancer
📎Epidemiology🌎
📎Pathogenesis🔬
📎Risk factors & surveillance🕵️
📎Diagnostics🩺
📎Treatment💊
📎Future directions🔍
… by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.
📎Epidemiology🌎
📎Pathogenesis🔬
📎Risk factors & surveillance🕵️
📎Diagnostics🩺
📎Treatment💊
📎Future directions🔍
… by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.
Reposted by TF Stoop
Congrats to #AnoukEmmen and @tfstoop.bsky.social for excellent presentations in the #PresidentialSession #AHPBA2025 AHPBA Miami 🇺🇸: #DIPLOMA2 RCT🇪🇺 robot/lap 🤖 vs open Whipple and #PREOPANC4🇳🇱 implementation of surgery for locally advanced #PancreaticCancer for @dpcgofficial.bsky.social and #EMIPS
March 21, 2025 at 2:01 PM
Congrats to #AnoukEmmen and @tfstoop.bsky.social for excellent presentations in the #PresidentialSession #AHPBA2025 AHPBA Miami 🇺🇸: #DIPLOMA2 RCT🇪🇺 robot/lap 🤖 vs open Whipple and #PREOPANC4🇳🇱 implementation of surgery for locally advanced #PancreaticCancer for @dpcgofficial.bsky.social and #EMIPS
Published in #hpbjournal, 🌎 survey on surgical management of pancreatic neck/body cancer with venous involvement:
📝222 surgeons, 49 countries, 6 continents
📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement
⚠️ Need for research 🔍
@eahpba.bsky.social @ihpba.bsky.social
📝222 surgeons, 49 countries, 6 continents
📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement
⚠️ Need for research 🔍
@eahpba.bsky.social @ihpba.bsky.social
March 16, 2025 at 7:46 AM
Published in #hpbjournal, 🌎 survey on surgical management of pancreatic neck/body cancer with venous involvement:
📝222 surgeons, 49 countries, 6 continents
📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement
⚠️ Need for research 🔍
@eahpba.bsky.social @ihpba.bsky.social
📝222 surgeons, 49 countries, 6 continents
📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement
⚠️ Need for research 🔍
@eahpba.bsky.social @ihpba.bsky.social
Reposted by TF Stoop
In JNCCN our nationwide study on quality of life in patients with locally advanced PDAC 🇳🇱
⭐️ QoL remains stable over time, regardless of receiving treatment (89%)
😱 Symptoms significantly deteriorate and deserve attention
➡️ Use in shared decision making
@dpcgofficial.bsky.social
⭐️ QoL remains stable over time, regardless of receiving treatment (89%)
😱 Symptoms significantly deteriorate and deserve attention
➡️ Use in shared decision making
@dpcgofficial.bsky.social
February 22, 2025 at 3:43 PM
In JNCCN our nationwide study on quality of life in patients with locally advanced PDAC 🇳🇱
⭐️ QoL remains stable over time, regardless of receiving treatment (89%)
😱 Symptoms significantly deteriorate and deserve attention
➡️ Use in shared decision making
@dpcgofficial.bsky.social
⭐️ QoL remains stable over time, regardless of receiving treatment (89%)
😱 Symptoms significantly deteriorate and deserve attention
➡️ Use in shared decision making
@dpcgofficial.bsky.social
In #BMC Cancer, #PREOPANC4 protocol to improve #LAPC care in 🇳🇱 @dpcgofficial.bsky.social with help of 4 international experts🇩🇪🇺🇸:
📎Multidisciplinary & surgical training program
📎Structured induction therapy, response evaluation & selection for surgery
📎National expertpanel
📎Patient-centered care
📎Multidisciplinary & surgical training program
📎Structured induction therapy, response evaluation & selection for surgery
📎National expertpanel
📎Patient-centered care
February 19, 2025 at 6:24 PM
In #BMC Cancer, #PREOPANC4 protocol to improve #LAPC care in 🇳🇱 @dpcgofficial.bsky.social with help of 4 international experts🇩🇪🇺🇸:
📎Multidisciplinary & surgical training program
📎Structured induction therapy, response evaluation & selection for surgery
📎National expertpanel
📎Patient-centered care
📎Multidisciplinary & surgical training program
📎Structured induction therapy, response evaluation & selection for surgery
📎National expertpanel
📎Patient-centered care
Reposted by TF Stoop
Looking back at an incredible #ALPS2025 meeting and delighted to have been awarded the Best Mini-Oral Presentation for our cost-analysis of robot vs open Whipple! Many thanks to the @amsterdamumc.bsky.social HPB-team @MichielFrancken @marcbesselink.bsky.social #roboticsurgery #pancreas
February 2, 2025 at 6:44 PM
Looking back at an incredible #ALPS2025 meeting and delighted to have been awarded the Best Mini-Oral Presentation for our cost-analysis of robot vs open Whipple! Many thanks to the @amsterdamumc.bsky.social HPB-team @MichielFrancken @marcbesselink.bsky.social #roboticsurgery #pancreas
Reposted by TF Stoop
Preoperative stereotactic radiotherapy to prevent pancreatic fistula in high-risk patients undergoing pancreatoduodenectomy (FIBROPANC): prospective multicentre phase II single-arm trial
➡️ doi.org/10.1093/bjs/...
➡️ doi.org/10.1093/bjs/...
Preoperative stereotactic radiotherapy to prevent pancreatic fistula in high-risk patients undergoing pancreatoduodenectomy (FIBROPANC): prospective multicentre phase II single-arm trial
The FIBROPANC study investigated the safety, feasibility, and efficacy of preoperative stereotactic radiotherapy on the pancreatic neck transection margin
doi.org
February 2, 2025 at 9:30 AM
Preoperative stereotactic radiotherapy to prevent pancreatic fistula in high-risk patients undergoing pancreatoduodenectomy (FIBROPANC): prospective multicentre phase II single-arm trial
➡️ doi.org/10.1093/bjs/...
➡️ doi.org/10.1093/bjs/...
Reposted by TF Stoop
Can prophylactic #Radiotherapy #SBRT in non-PDAC #pancreatoduodenectomy prevent fistula POPF?
🔑 “it works but doesn’t help”
▶️#FIBROPANC published today @bjsurgery.bsky.social @dpcgofficial.bsky.social @eahpba.bsky.social @ihpba.bsky.social
academic.oup.com/bjs/article/...
🔑 “it works but doesn’t help”
▶️#FIBROPANC published today @bjsurgery.bsky.social @dpcgofficial.bsky.social @eahpba.bsky.social @ihpba.bsky.social
academic.oup.com/bjs/article/...
February 1, 2025 at 1:23 PM
Can prophylactic #Radiotherapy #SBRT in non-PDAC #pancreatoduodenectomy prevent fistula POPF?
🔑 “it works but doesn’t help”
▶️#FIBROPANC published today @bjsurgery.bsky.social @dpcgofficial.bsky.social @eahpba.bsky.social @ihpba.bsky.social
academic.oup.com/bjs/article/...
🔑 “it works but doesn’t help”
▶️#FIBROPANC published today @bjsurgery.bsky.social @dpcgofficial.bsky.social @eahpba.bsky.social @ihpba.bsky.social
academic.oup.com/bjs/article/...
In JAMA Oncology our 🌎 @eahpba.bsky.social study on adjuvant chemo (AT) in 742 resected localized #PDAC patients following NAT #FFX (40 centers):
📌OS ⬆️ by AT;
… only with multi-agent AT ⚠️
📌Possibly less effect of AT if >=8c NAT FFX, RECIST response, ypN0 & head tumor 📣
📯RCT🟰🔑
📌OS ⬆️ by AT;
… only with multi-agent AT ⚠️
📌Possibly less effect of AT if >=8c NAT FFX, RECIST response, ypN0 & head tumor 📣
📯RCT🟰🔑
January 23, 2025 at 9:51 PM
In JAMA Oncology our 🌎 @eahpba.bsky.social study on adjuvant chemo (AT) in 742 resected localized #PDAC patients following NAT #FFX (40 centers):
📌OS ⬆️ by AT;
… only with multi-agent AT ⚠️
📌Possibly less effect of AT if >=8c NAT FFX, RECIST response, ypN0 & head tumor 📣
📯RCT🟰🔑
📌OS ⬆️ by AT;
… only with multi-agent AT ⚠️
📌Possibly less effect of AT if >=8c NAT FFX, RECIST response, ypN0 & head tumor 📣
📯RCT🟰🔑
PVR 1-2 vs 3-4 during pancreatoduodenectomy for resectable #PDAC with venous involvement?
In Annals of Surgery, our observational study with 357 patients from 🇸🇪🇯🇵🇳🇱🇺🇸:
📌PVR type NOT associated with OS, locoregional recurrence & major morbidity
➡️ surgeon’s personal preference
In Annals of Surgery, our observational study with 357 patients from 🇸🇪🇯🇵🇳🇱🇺🇸:
📌PVR type NOT associated with OS, locoregional recurrence & major morbidity
➡️ surgeon’s personal preference
January 23, 2025 at 4:33 PM
PVR 1-2 vs 3-4 during pancreatoduodenectomy for resectable #PDAC with venous involvement?
In Annals of Surgery, our observational study with 357 patients from 🇸🇪🇯🇵🇳🇱🇺🇸:
📌PVR type NOT associated with OS, locoregional recurrence & major morbidity
➡️ surgeon’s personal preference
In Annals of Surgery, our observational study with 357 patients from 🇸🇪🇯🇵🇳🇱🇺🇸:
📌PVR type NOT associated with OS, locoregional recurrence & major morbidity
➡️ surgeon’s personal preference
Reposted by TF Stoop
Neoadjuvant chemotherapy for left 👈 sided resectable #PDAC
🪡 72% of US received adjuvant
💉 NAT had better OS (53 🆚 37 months)
🤏 Tumor size and 🧪 elevated CA19.9 correlates with benefits of NAT
And now… time for RCT! 💪
#HPBSky
www.annalsofoncology.org/article/S092...
🪡 72% of US received adjuvant
💉 NAT had better OS (53 🆚 37 months)
🤏 Tumor size and 🧪 elevated CA19.9 correlates with benefits of NAT
And now… time for RCT! 💪
#HPBSky
www.annalsofoncology.org/article/S092...
January 17, 2025 at 9:52 PM
Neoadjuvant chemotherapy for left 👈 sided resectable #PDAC
🪡 72% of US received adjuvant
💉 NAT had better OS (53 🆚 37 months)
🤏 Tumor size and 🧪 elevated CA19.9 correlates with benefits of NAT
And now… time for RCT! 💪
#HPBSky
www.annalsofoncology.org/article/S092...
🪡 72% of US received adjuvant
💉 NAT had better OS (53 🆚 37 months)
🤏 Tumor size and 🧪 elevated CA19.9 correlates with benefits of NAT
And now… time for RCT! 💪
#HPBSky
www.annalsofoncology.org/article/S092...
NAT for left-sided RPC?
In Annals of Oncology our 🌎 observational study on #NAT vs #US in 2282 patients with resected left-sided #RPC (76 centers):
📌OS⬆️after NAT vs US
… 5y OS 47% vs 35%
📌NAT effect⬆️in large tumors & higher CA19.9 at diagnosis
🔑🟰ABC-approach
📯RCT
See full text below 👇
In Annals of Oncology our 🌎 observational study on #NAT vs #US in 2282 patients with resected left-sided #RPC (76 centers):
📌OS⬆️after NAT vs US
… 5y OS 47% vs 35%
📌NAT effect⬆️in large tumors & higher CA19.9 at diagnosis
🔑🟰ABC-approach
📯RCT
See full text below 👇
January 13, 2025 at 8:24 AM
Reposted by TF Stoop
Perioperative therapy for #Pancreas Cancer
⭐️ A stellar lecture by the great Matthew H Katz 🇺🇸 @mdanderson.bsky.social ⭐️
All you need to know, and future perspectives in the eyes of a true pioneer of neoadjuvant chemo #HPBSky #SurgSky #MedSky
youtube.com/watch?v=kIlH...
⭐️ A stellar lecture by the great Matthew H Katz 🇺🇸 @mdanderson.bsky.social ⭐️
All you need to know, and future perspectives in the eyes of a true pioneer of neoadjuvant chemo #HPBSky #SurgSky #MedSky
youtube.com/watch?v=kIlH...
November 19, 2024 at 1:17 PM
Perioperative therapy for #Pancreas Cancer
⭐️ A stellar lecture by the great Matthew H Katz 🇺🇸 @mdanderson.bsky.social ⭐️
All you need to know, and future perspectives in the eyes of a true pioneer of neoadjuvant chemo #HPBSky #SurgSky #MedSky
youtube.com/watch?v=kIlH...
⭐️ A stellar lecture by the great Matthew H Katz 🇺🇸 @mdanderson.bsky.social ⭐️
All you need to know, and future perspectives in the eyes of a true pioneer of neoadjuvant chemo #HPBSky #SurgSky #MedSky
youtube.com/watch?v=kIlH...
Reposted by TF Stoop
2025 Multi-Societal #European #Guideline on #PancreaticCancer
✅ Meeting with our 39 amazing Research leads to discuss group progress and any issues
▶️ 30 Societies
▶️ 13 Working groups
▶️ Focus on knowledge gaps
@eahpba.bsky.social Laura Leeuwenburgh, Magdalena Holze, Elena Rangelova
✅ Meeting with our 39 amazing Research leads to discuss group progress and any issues
▶️ 30 Societies
▶️ 13 Working groups
▶️ Focus on knowledge gaps
@eahpba.bsky.social Laura Leeuwenburgh, Magdalena Holze, Elena Rangelova
December 3, 2024 at 5:03 PM
2025 Multi-Societal #European #Guideline on #PancreaticCancer
✅ Meeting with our 39 amazing Research leads to discuss group progress and any issues
▶️ 30 Societies
▶️ 13 Working groups
▶️ Focus on knowledge gaps
@eahpba.bsky.social Laura Leeuwenburgh, Magdalena Holze, Elena Rangelova
✅ Meeting with our 39 amazing Research leads to discuss group progress and any issues
▶️ 30 Societies
▶️ 13 Working groups
▶️ Focus on knowledge gaps
@eahpba.bsky.social Laura Leeuwenburgh, Magdalena Holze, Elena Rangelova